You can buy Lucielafib at the lowest price in the online pharmacy Nextgen.ooo . Odevixibat is an sodium/bile acid cotransporter inhibitor indicated in the treatment of pruritus in patients with progressive familial intrahepatic cholestasis. Odevixibat is the first approved non-surgical treatment option for progressive familial intrahepatic cholestasis.Odevixibat was granted FDA and Health Canada approval on 20 July 2021 and 13 November 2023 respectively. It is also indicated for the treatment of cholestatic pruritus in patients 12 months of age and older with Alagille Syndrome. Odevixibat may not be effective in patients with ABCB11 variants since these patients lack a functional bile salt export pump.Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist 2 that works to inhibit bile acid synthesis. On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis. The drug was also approved by the EMA on September 23, 2024. Elafibranor is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults who have had an inadequate response to ursodeoxycholic acid, or as monotherapy in patients unable to tolerate ursodeoxycholic acid. In the US, this indication is approved under accelerated approval and is subject to change based on the determined clinical benefit of the drug in future confirmatory trials. 
 
Proliferator-activated receptor (PPAR) is a nuclear receptor that regulates numerical cellular processes, including lipid metabolism and inflammation. Different subtypes of PPARs have different roles and functions, and two of these subtypes - PPAR-alpha (α) and PPAR-delta (δ) (also known as PPARβ) - have been identified as therapeutic targets for diabetes and lipid disorders. PPARα controls lipid flux in the liver and regulates plasma levels of triglycerides and high-density lipoprotein (HDL) cholesterol. PPARδ activation leads to fatty acid transport and oxidation, increased HDL levels, and improved glucose homeostasis. PPARα and PPARδ also mediate anti-inflammatory actions. While the exact mechanism of action has not been fully elucidated, elafibranor and its active metabolite (GFT1007) are dual α and β/δ agonists. The signalling pathway for PPARδ was reported to include Fibroblast Growth Factor 21 (FGF21)-dependent downregulation of CYP7A1, the key enzyme for the synthesis of bile acids from cholesterol.